利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.033 秒)

    Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    1.
    发明授权
    Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells 有权
    突变的抗CD22抗体对表达CD22的白血病细胞的亲和力增加

    公开(公告)号：US07777019B2

    公开(公告)日：2010-08-17

    申请号：US12030828

    申请日：2008-02-13

    申请人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert J. Kreitman

    发明人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert J. Kreitman

    IPC分类号： C07H21/04 ,  A61K39/395 ,  C07K16/00

    CPC分类号： C07K16/2803 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624

    摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

    摘要翻译： 重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。 与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。 用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。 将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

    Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
    2.
    发明申请
    Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells 有权
    突变的抗cd22抗体与对表达CD22的白血病细胞的亲和性增加

    公开(公告)号：US20050118182A1

    公开(公告)日：2005-06-02

    申请号：US10490535

    申请日：2002-09-25

    申请人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    发明人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    IPC分类号： A61K47/48 ,  C07K16/28 ,  A61K39/40 ,  C07K16/46

    CPC分类号： C07K16/2803 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624

    摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

    摘要翻译： 重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。 与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。 用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。 将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
    3.
    发明授权
    Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells 有权
    突变的抗CD22抗体对表达CD22的白血病细胞的亲和力增加

    公开(公告)号：US08809502B2

    公开(公告)日：2014-08-19

    申请号：US13438725

    申请日：2012-04-03

    申请人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    发明人： Ira Pastan ,  Giuliana Salvatore ,  Richard Beers ,  Robert Kreitman

    IPC分类号： A61K39/00

    CPC分类号： C07K16/2803 ,  A61K47/6829 ,  A61K47/6849 ,  A61K47/6875 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/624

    摘要： Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 antigen of B cells and B cell malignancies compared to RFB4. Immunotoxins made with the antibodies and antibody fragments of the invention have improved cytotoxicity to CD22-expressing cancer cells. Compositions that incorporate these antibodies into chimeric immunotoxin molecules that can be used in medicaments and methods for inhibiting the growth and proliferation of leukemia and lymphoma cells.

    摘要翻译： 重组免疫毒素是由与细菌或植物毒素融合的抗体的Fv结构域组成的融合蛋白。 RFB4（Fv）-PE38是靶向在B细胞和B细胞恶性肿瘤上表达的CD22的免疫毒素。 与RFB4相比，本发明提供了具有改善的结合B细胞和B细胞恶性肿瘤的CD22抗原的能力的抗体和抗体片段。 用本发明的抗体和抗体片段制备的免疫毒素对表达CD22的癌细胞具有改善的细胞毒性。 将这些抗体并入可用于药物的嵌合免疫毒素分子中的组合物和用于抑制白血病和淋巴瘤细胞生长和增殖的方法。

    Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
    6.
    发明授权
    Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof 有权
    抗EGFRvIII scFv具有改善的细胞毒性和产量，基于其的免疫毒素及其使用方法

    公开(公告)号：US07129332B2

    公开(公告)日：2006-10-31

    申请号：US10203675

    申请日：2001-02-23

    申请人： Ira Pastan ,  Richard Beers ,  Partha S. Chowdhury ,  Darell Bigner

    发明人： Ira Pastan ,  Richard Beers ,  Partha S. Chowdhury ,  Darell Bigner

    IPC分类号： C12P21/08 ,  A61K39/395 ,  C07H21/04 ,  C12P21/04

    CPC分类号： C07K16/2863 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/00

    摘要： The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions (“CDRs”) of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.

    摘要翻译： 本发明提供抗体，其被称为EGFRvIII的表皮生长因子受体的突变体形式，其仅在或者主要在胶质母细胞瘤细胞的表面上以及乳腺，卵巢和非小细胞肺癌的细胞上发现。 由本发明提供的抗体具有指定为MR1的scFv的互补决定区（“CDR”），但在重链可变区的CDR3中的位置98和99具有突变，并且任选地在其它CDR中。 特别地，本发明提供了称为MR1-1的抗体，其在VH和VL链的CDR3中突变MR1。 本发明提供了另外的抗体，其中MR1在VH或VL的CDR1和2中突变，或两者均突变。

    Gene expressed in prostate cancer, methods and use thereof
    8.
    发明授权
    Gene expressed in prostate cancer, methods and use thereof 失效
    在前列腺癌中表达的基因，其方法和用途

    公开(公告)号：US07572887B2

    公开(公告)日：2009-08-11

    申请号：US10552515

    申请日：2004-04-05

    申请人： Ira Pastan ,  Tapan K. Bera ,  Byungkook Lee

    发明人： Ira Pastan ,  Tapan K. Bera ,  Byungkook Lee

    IPC分类号： C07K14/00 ,  C07H21/04 ,  C12N15/00 ,  C12Q1/68

    CPC分类号： A61K38/168 ,  A61K38/164 ,  A61K47/64 ,  C07K14/47 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106 ,  G01N33/57434 ,  G01N2500/00

    摘要： A polypeptide is disclosed that is specifically detected in the cells of the prostate, termed Splice Variant-Novel Gene Expressed in Prostate (SV-NGEP). Polynucleotides encoding SV-NGEP are also disclosed, as are vectors including these polynucleotides. Host cells transformed with these polynucleotides are also disclosed. Antibodies and immunoconjugages are disclosed that specifically bind SV-NGEP. Methods are disclosed for using an NGEP polypeptide, an antibody that specifically binds SV-NGEP, or a polynucleotide encoding SV-NGEP. Assays are disclosed for the detection of prostate cancer. Pharmaceutical compositions including an SV-NGEP polypeptide, an antibody that specifically binds SV-NEGP, or a polynucleotide encoding SV-NGEP are also disclosed. These pharmaceutical compositions are of use in the treatment of prostate cancer.

    摘要翻译： 公开了在前列腺细胞中特异性检测到的多肽，称为前列腺中表达的剪接变体 - 新型基因（SV-NGEP）。 还公开了编码SV-NGEP的多核苷酸，以及包括这些多核苷酸的载体。 还公开了用这些多核苷酸转化的宿主细胞。 公开了特异性结合SV-NGEP的抗体和免疫结合物。 公开了使用NGEP多肽，特异性结合SV-NGEP的抗体或编码SV-NGEP的多核苷酸的方法。 公开了检测前列腺癌的测定。 还公开了包含SV-NGEP多肽，特异性结合SV-NEGP的抗体或编码SV-NGEP的多核苷酸的药物组合物。 这些药物组合物可用于治疗前列腺癌。

    Page-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
    9.
    发明申请
    Page-4, an X-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor 审中-公开
    第4页，在正常和肿瘤前列腺，睾丸和子宫中表达的X连接的量规样基因，并用于其

    公开(公告)号：US20070248972A1

    公开(公告)日：2007-10-25

    申请号：US11704714

    申请日：2007-02-09

    申请人： Ira Pastan ,  Ulrich Brinkmann ,  George Vasmatzis ,  Byungkook Lee

    发明人： Ira Pastan ,  Ulrich Brinkmann ,  George Vasmatzis ,  Byungkook Lee

    IPC分类号： C12Q1/68 ,  C07H21/00 ,  C12N1/00 ,  C12N1/21 ,  C12N15/00 ,  C12N5/00

    CPC分类号： C07K14/4748 ,  A61K39/00

    摘要： PAGE-4 is a gene preferentially expressed in normal male and female reproductive tissues, prostate, testis, fallopian tube, uterus and placenta, as well as in prostate cancer, testicular cancer and uterine cancer. This expression pattern makes it a target for diagnosis and for vaccine based therapy of neoplasms of prostate, testis and uterus. The invention provides immunogenic compositions comprising PAGE-4 protein or immunogenic peptides thereof, methods of inhibiting the growth of malignant cells expressing PAGE-4, and methods of inducing an enhanced immune response to PAGE-4-expressing cancers.

    摘要翻译： PAGE-4是在正常男性和女性生殖组织，前列腺，睾丸，输卵管，子宫和胎盘以及前列腺癌，睾丸癌和子宫癌中优先表达的基因。 这种表达模式使其成为诊断和基于疫苗的前列腺，睾丸和子宫肿瘤的治疗的目标。 本发明提供包含PAGE-4蛋白或其免疫原性肽的免疫原性组合物，抑制表达PAGE-4的恶性细胞生长的方法，以及诱导对表达PAGE-4的癌症增强的免疫应答的方法。